Darzalex' 2020 sales reach prognosis peak
Johnson & Johnson's sales of the Genmab-developed drug Darzalex has continued its growth in Q4, and so, the drug has reached the upper end of expected sales.
- Genmab CEO brushes off conflict with Janssen: "It's business as usual"
- Leo Pharma goes head to head with Janssen in new psoriasis trial
For abonnenter